ORIC Pharmaceuticals Stock (NASDAQ:ORIC)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$11.44

52W Range

$3.90 - $14.67

50D Avg

$9.35

200D Avg

$8.45

Market Cap

$952.81M

Avg Vol (3M)

$1.17M

Beta

1.53

Div Yield

-

ORIC Company Profile


ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

122

IPO Date

Apr 24, 2020

Website

ORIC Performance


ORIC Financial Summary


Dec 24Dec 23Dec 22
Revenue---
Operating Income$-142.90M$-110.78M$-91.77M
Net Income$-127.85M$-100.70M$-91.48M
EBITDA$-142.90M$-109.75M$-91.77M
Basic EPS$-1.83$-1.96$-2.31
Diluted EPS$-1.83$-1.96$-2.31

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q4 21Mar 21, 22 | 5:00 PM

Peer Comparison


TickerCompany
RVMDRevolution Medicines, Inc.
ZNTLZentalis Pharmaceuticals, Inc.
PMVPPMV Pharmaceuticals, Inc.
KROSKeros Therapeutics, Inc.
PASGPassage Bio, Inc.
OLMAOlema Pharmaceuticals, Inc.
BCABBioAtla, Inc.
IKNAIkena Oncology, Inc.
PCVXVaxcyte, Inc.